Structural and functional characterization of an epitope in the conserved C-terminal region of HIV-1 gp120. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Structural and functional characterization of an epitope in the conserved C-terminal region of HIV-1 gp120.

J Pept Res. 1999 Jul;54(1):32-42. Unique Identifier : AIDSLINE MED/99376198
Ferrer M; Sullivan BJ; Godbout KL; Burke E; Stump HS; Godoy J; Golden A; Profy AT; van Schravendijk MR; Department of Molecular and Cellular Biology, Harvard University,; Cambridge, MA 02138, USA.


Abstract: Through an integrated study of the reactivity of a monoclonal antibody, 803-15.6, with synthetic peptides and native recombinant HIV-1 envelope glycoprotein gp120, we have obtained structure-functional information on a region of rgp120 not yet elucidated by X-ray crystallography. mAb 803-15.6 binds with high affinity and broad cross-clade specificity to the conserved C-terminal region (amino acids 502-516) of HIV-1 rgp120. Phage display selection from a random peptide library identified the core binding motif as AXXKXRH, homologous to residues 502-508. Using quantitative binding analyses, the affinity of mAb 803-15.6 for native, monomeric recombinant gp120HXB2 (rgp120) was found to be similar to that for the synthetic gp120 peptide (502-516). Circular dichroism studies indicate that the synthetic peptide largely has a random coil conformation in solution. The results therefore suggest that the 803-15.6 epitope is fully accessible on rgp120 and that this region of rgp120 is as flexible as the synthetic peptide. Residues 502-504 are on the edge of a putative gp41 binding site that has been postulated to change conformation on CD4 binding. However, the affinity of mAb 803-15.6 for rgp120 is not affected by binding of CD4 and vice-versa. These results suggest either that the 502-504 region does not change conformation upon CD4 binding, or that recombinant gp120 does not undergo the same changes as occur in the native viral gp120-gp41 oligomer. The detailed characterization of the 803-15.6 epitope may be useful for further study of the role of the C5 region of gp120 in the viral attachment and fusion process.
Keywords: JOURNAL ARTICLE Amino Acid Sequence Animal Antigens, CD4/METABOLISM Binding Sites Circular Dichroism Conserved Sequence Epitope Mapping Epitopes/*CHEMISTRY/METABOLISM Female HIV Envelope Protein gp120/*CHEMISTRY/METABOLISM HIV-1/*CHEMISTRY Mice Mice, Inbred BALB C Molecular Sequence Data Protein Conformation Recombinant Proteins/CHEMISTRY/METABOLISM Structure-Activity Relationship Support, Non-U.S. Gov't Surface Plasmon ResonanceKWDjournalarticleaminoacidsequenceanimalantigens,cd4/metabolismbindingsitescirculardichroismconservedsequenceepitopemappingepitopes/KWDchemistry/metabolismfemalehivenvelopeproteingp120/KWDchemistry/metabolismhiv-1/KWDchemistrymicemice,inbredbalbcmolecularsequencedataproteinconformationrecombinantproteins/chemistry/metabolismstructure-activityrelationshipsupport,non-uKWDsKWDgov'tsurfaceplasmonresonance
991230
A99C0999

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .